State Street Corp increased its holdings in Stryker Corporation (NYSE:SYK – Free Report) by 1.7% in the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 15,799,557 shares of the medical technology company’s stock after acquiring an additional 266,992 shares during the period. State Street Corp’s holdings in Stryker were worth $4,364,738,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in SYK. Gables Capital Management Inc. purchased a new stake in Stryker in the second quarter valued at $25,000. Kilter Group LLC purchased a new position in shares of Stryker during the 2nd quarter worth $25,000. Cornerstone Financial Management LLC grew its holdings in shares of Stryker by 66.0% during the 2nd quarter. Cornerstone Financial Management LLC now owns 78 shares of the medical technology company’s stock worth $25,000 after purchasing an additional 31 shares during the period. Highland Investment Advisors LLC acquired a new stake in shares of Stryker during the 2nd quarter worth about $25,000. Finally, Compass Financial Management LLC acquired a new stake in shares of Stryker during the 2nd quarter worth about $27,000. Institutional investors and hedge funds own 77.09% of the company’s stock.
Insider Buying and Selling at Stryker
In related news, Director Ronda Stryker sold 550,000 shares of the company’s stock in a transaction that occurred on Friday, November 6th. The shares were sold at an average price of $325.32, for a total transaction of $178,926,000.00. Following the sale, the director directly owned 1,701,375 shares of the company’s stock, valued at $553,491,315. This represents a 24.43% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 4.60% of the company’s stock.
Stryker Price Performance
SYK stock opened at $309.91 on Friday. The business’s fifty day moving average price is $295.66 and its 200 day moving average price is $321.39. Stryker Corporation has a 12-month low of $267.00 and a 12-month high of $389.33. The company has a market capitalization of $117.98 billion, a PE ratio of 33.00, a P/E/G ratio of 2.13 and a beta of 0.78. The company has a current ratio of 2.18, a quick ratio of 1.30 and a debt-to-equity ratio of 0.60.
Stryker (NYSE:SYK – Get Free Report) last issued its quarterly earnings results on Thursday, October 29th. The medical technology company reported $3.52 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.55 by ($0.03). The business had revenue of $6.52 billion for the quarter, compared to analysts’ expectations of $6.62 billion. Stryker had a return on equity of 23.74% and a net margin of 13.78%. The firm’s revenue for the quarter was up 7.6% on a year-over-year basis. During the same quarter last year, the company earned $3.19 earnings per share. On average, sell-side analysts anticipate that Stryker Corporation will post 14.85 EPS for the current year.
Wall Street Analyst Weigh In
Several analysts recently issued reports on the stock. Canaccord Genuity Group lowered shares of Stryker from a “buy” rating to a “hold” rating and reduced their price objective for the company from $385.00 to $300.00 in a report on Friday, October 30th. Stifel Nicolaus lowered their target price on shares of Stryker from $330.00 to $325.00 and set a “buy” rating for the company in a research note on Monday, November 2nd. Wall Street Zen cut shares of Stryker from a “buy” rating to a “hold” rating in a research report on Saturday, October 3rd. BTIG Research boosted their price target on shares of Stryker from $304.00 to $345.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, TD Cowen decreased their price objective on shares of Stryker from $298.00 to $290.00 and set a “hold” rating on the stock in a report on Friday, October 30th. Twenty-one research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $343.77.
Stryker Company Profile
Stryker is a medical technology company that develops and sells products and services for healthcare providers. Its offerings include orthopedic implants and surgical equipment, neurotechnology and spine products, and medical and surgical equipment used in hospitals and other care settings. The company’s products also include patient-handling and emergency medical equipment, as well as instruments and technologies that support surgical procedures. Stryker serves healthcare customers in the United States and internationally.
Further Reading
- Five stocks we like better than Stryker
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK – Free Report).
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.
